GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jaguar Health Inc (NAS:JAGX) » Definitions » Earnings Yield (Joel Greenblatt) %

Jaguar Health (Jaguar Health) Earnings Yield (Joel Greenblatt) % : -73.53% (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Jaguar Health Earnings Yield (Joel Greenblatt) %?

Jaguar Health's Enterprise Value for the quarter that ended in Mar. 2024 was $46.19 Mil. Jaguar Health's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-34.06 Mil. Jaguar Health's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2024 was -73.53%.

The historical rank and industry rank for Jaguar Health's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

JAGX' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -293.31   Med: -101.74   Max: -7.05
Current: -80

During the past 11 years, the highest Earnings Yield (Joel Greenblatt) of Jaguar Health was -7.05%. The lowest was -293.31%. And the median was -101.74%.

JAGX's Earnings Yield (Joel Greenblatt) % is ranked worse than
82.08% of 1412 companies
in the Biotechnology industry
Industry Median: -15.85 vs JAGX: -80.00

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Jaguar Health's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2024 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Jaguar Health Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for Jaguar Health's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jaguar Health Earnings Yield (Joel Greenblatt) % Chart

Jaguar Health Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings Yield (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -188.68 -32.15 -70.42 -83.33 -85.47

Jaguar Health Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Earnings Yield (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -111.11 -104.17 -82.64 -85.47 -73.53

Competitive Comparison of Jaguar Health's Earnings Yield (Joel Greenblatt) %

For the Biotechnology subindustry, Jaguar Health's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jaguar Health's Earnings Yield (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jaguar Health's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Jaguar Health's Earnings Yield (Joel Greenblatt) % falls into.



Jaguar Health Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

Jaguar Healths Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2023 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=-35.519/41.6757282
=-85.23 %

Jaguar Health's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-34.06 Mil.



Jaguar Health  (NAS:JAGX) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


Jaguar Health Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Jaguar Health's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Jaguar Health (Jaguar Health) Business Description

Industry
Traded in Other Exchanges
Address
200 Pine Street, Suite 400, San Francisco, CA, USA, 94104
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments-human health and animal health. The company generates the majority of its revenue from the Human Health segment.
Executives
Anula Jayasuriya director 5150 EL CAMINO REAL, SUITE #A-32, LOS ALTOS CA 94022
Pravin R Chaturvedi officer: Chief Scientific Officer C/O JAGUAR HEALTH INC., 200 PINE STREET, SUITE 400, SAN FRANCISCO CA 94104
Lisa A Conte director, officer: CEO & President 213 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Carol R. Lizak officer: Chief Accounting Officer 201 MISSION STREET, SUITE 2375, SAN FRANCISCO CA 94105
James J Bochnowski director C/O DELPHI VENTURES, 160 BOVET RD, SUITE 408, SAN MATEO CA 94402
Jonathan S. Wolin officer: Chief of Staff, CCO & GC 201 MISSION STREET, SUITE 2375, SAN FRANCISCO CA 94105
Jonathan B. Siegel director C/O KINGDON CAPITAL MANAGEMENT, L.L.C., 152 WEST 57TH STREET, 50TH FLOOR, NEW YORK NY 10019
Bryan Ezralow 1994 Trust Dated December 22, 1994 10 percent owner 23622 CALABASAS ROAD, SUITE 200, CALABASAS CA 91302
Bryan Ezralow 10 percent owner THE EZRALOW CO, LLC, 23622 CALABASAS ROAD, SUITE 200, CALABASAS CA 91302-1549
Nantucket Investments Ltd 10 percent owner PO BOX 282, REGENCY COURT, GLATEGNY ESPLANADE, ST PETER PORT Y7 GY1 3RH
Jonathan M Glaser 10 percent owner 11601 WILSHIRE BLVD., SUITE 2180, LOS ANGELES CA 90025
Murray David Macnaughtan director C/O JAGUAR HEALTH, INC., 201 MISSION STREET, SUITE 2375, SAN FRANCISCO CA 94105
Greg J Divis director 10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15
Jeffery C. Johnson director C/O SAGARD CAPITAL PARTNERS, L.P., 280 PARK AVENUE, 3F WEST, STAMFORD CT 06901
Sagard Capital Partners, L.p. 10 percent owner 280 PARK AVENUE, 3RD FLOOR WEST, NEW YORK NY 10017

Jaguar Health (Jaguar Health) Headlines

From GuruFocus